View Single Post
Old 12-20-2009, 08:29 AM   #5
gdpawel
Senior Member
 
gdpawel's Avatar
 
Join Date: Aug 2006
Location: Pennsylvania
Posts: 1,080
Re: Insulin potentiated therapy (IPT)

Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, in an article response to the Cancer Genome Project says, "We're going to be able to take a cancer specimen, analyze it, and follow those genetic changes that influence particular pathways, then we'll use one, two, three or more targeted therapies, perhaps simultaneously, and be able to completely interrupt the flow of the cancer process."

According to Dr. Arny Glazier, a cancer researcher (former oncology fellow at Johns Hopkins), in his book Cure: Scientific, Social and Organizational Requirements for the Specific Cure of Cancer, "the consistent and specific cure or control of cancer will require multiple drugs administered in combination targeted to abnormal patterns of normal cellular machinery that effect or reflect malignant behavior. Finding the 'patterns' of malignant cells and developing a set of 5 to10 drugs in order to cure or control cancer."

So the consistent and specific cure of cancer requires therapy that can target the set of "all" malignant cells that could evolve in the human body. It is thought that each anti-cancer drug needs to be given at a dose sufficient to kill cells that express the pattern targeted by the individual drug. In order to kill "all" patterns of malignant cells, you need to give full doses of all drugs (5-10) in combination.

However, it is not possible to give five to ten existing drugs together in combination, the toxicity would be prohibitive. They have overlapping toxicity, which means you need to cut the doses when you give them together, so you get down to homeopathic dose levels.

This could be overcomed with Potentiation Therapy (IPT) or "low dose chemotherapy," which makes cell membranes more permeable and increases uptake of drugs into cells. IPT selectively targets tumor cells, which usually have more insulin receptors than normal cells. Makes tumor cells more susceptible to chemo by modifying cell metabolism. As a result, cancer patients can greatly reduce chemo dosage (reduce it to only 10-15%), while at the same time, receive the 5-10 drugs in order to effectively cure or control cancer, and eliminate most side effects while increasing the effectiveness of chemo (chemo synthesizer).

Given the current state of the art, in vitro drug sensitivity testing could be of significant clinical value. Upgrading clinical therapy by using drug sensitivity assays measuring "cell death" of three dimensional microclusters of live "fresh" tumor cells, can improve the situation by allowing more drugs to be considered. The more drug types there are in the selective arsenal, the more likely the system is to prove beneficial.

Cell culture assays tests with cell-death endpoints are the Rosetta Stone which allows for identification of clinically relevant gene expression patterns which correlate with clinical drug resistance and sensitivity for different drugs in specific diseases. There is no single gene whose expression accurately predicts therapy outcome, emphasizing that cancer is a complex disease and needs to be attacked on many fronts.

A number of cell culture assay labs across the country have data from tens of thousands of fresh human tumor specimens, representing virtually all types of human solid and hematologic neoplasms. Cell culture assay labs have the database necessary to define sensitivity and resistance for virtually all of the currently available drugs in virtually all types of human solid and hematologic neoplasms.

Fresh Human Tumor Cell Culture Atlas:

http://weisenthal.org/Human_Tumor_As...nal/Atlas.html

Is this possible? Yes! Will the "powers that be" allow it to happen? You'll have to answer that question.
gdpawel is offline   Reply With Quote